Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Identification of Resistance Pathways Specific to Malignancy Using Organoid Models of Pancreatic Cancer.

Ponz-Sarvise M, Corbo V, Tiriac H, Engle DD, Frese KK, Oni TE, Hwang CI, Öhlund D, Chio IIC, Baker LA, Filippini D, Wright K, Bapiro TE, Huang P, Smith P, Yu KH, Jodrell DI, Park Y, Tuveson DA.

Clin Cancer Res. 2019 Nov 15;25(22):6742-6755. doi: 10.1158/1078-0432.CCR-19-1398. Epub 2019 Sep 6.

PMID:
31492749
2.

Herbal Remedies: Throwing Off Phenotype Prediction-A Culprit for Pharmacogenomic-Guided Drug Therapy and Drug Safety.

Dandara C, Thomford NE, Bapiro TE.

Clin Pharmacol Ther. 2019 Aug;106(2):302-304. doi: 10.1002/cpt.1509. Epub 2019 Jun 27. No abstract available.

PMID:
31245840
3.

Complete Substrate Inhibition of Cytochrome P450 2C8 by AZD9496, an Oral Selective Estrogen Receptor Degrader.

Bapiro TE, Sykes A, Martin S, Davies M, Yates JWT, Hoch M, Rollison HE, Jones B.

Drug Metab Dispos. 2018 Sep;46(9):1268-1276. doi: 10.1124/dmd.118.081539. Epub 2018 Jun 19. Erratum in: Drug Metab Dispos. 2019 Aug;47(8):883.

PMID:
29921707
4.

Mechanistic Distinctions between CHK1 and WEE1 Inhibition Guide the Scheduling of Triple Therapy with Gemcitabine.

Koh SB, Wallez Y, Dunlop CR, Bernaldo de Quirós Fernández S, Bapiro TE, Richards FM, Jodrell DI.

Cancer Res. 2018 Jun 1;78(11):3054-3066. doi: 10.1158/0008-5472.CAN-17-3932. Epub 2018 May 7.

5.

Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer.

Hessmann E, Patzak MS, Klein L, Chen N, Kari V, Ramu I, Bapiro TE, Frese KK, Gopinathan A, Richards FM, Jodrell DI, Verbeke C, Li X, Heuchel R, Löhr JM, Johnsen SA, Gress TM, Ellenrieder V, Neesse A.

Gut. 2018 Mar;67(3):497-507. doi: 10.1136/gutjnl-2016-311954. Epub 2017 Jan 10.

6.
7.

Anti-stromal treatment together with chemotherapy targets multiple signalling pathways in pancreatic adenocarcinoma.

Carapuça EF, Gemenetzidis E, Feig C, Bapiro TE, Williams MD, Wilson AS, Delvecchio FR, Arumugam P, Grose RP, Lemoine NR, Richards FM, Kocher HM.

J Pathol. 2016 Jul;239(3):286-96. doi: 10.1002/path.4727. Epub 2016 May 25.

8.

Gemcitabine diphosphate choline is a major metabolite linked to the Kennedy pathway in pancreatic cancer models in vivo.

Bapiro TE, Frese KK, Courtin A, Bramhall JL, Madhu B, Cook N, Neesse A, Griffiths JR, Tuveson DA, Jodrell DI, Richards FM.

Br J Cancer. 2014 Jul 15;111(2):318-25. doi: 10.1038/bjc.2014.288. Epub 2014 May 29.

9.

SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice.

Neesse A, Frese KK, Chan DS, Bapiro TE, Howat WJ, Richards FM, Ellenrieder V, Jodrell DI, Tuveson DA.

Gut. 2014 Jun;63(6):974-83. doi: 10.1136/gutjnl-2013-305559. Epub 2013 Sep 25.

10.

Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer.

Courtin A, Richards FM, Bapiro TE, Bramhall JL, Neesse A, Cook N, Krippendorff BF, Tuveson DA, Jodrell DI.

PLoS One. 2013 Jun 28;8(6):e67330. doi: 10.1371/journal.pone.0067330. Print 2013.

11.

CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer.

Neesse A, Frese KK, Bapiro TE, Nakagawa T, Sternlicht MD, Seeley TW, Pilarsky C, Jodrell DI, Spong SM, Tuveson DA.

Proc Natl Acad Sci U S A. 2013 Jul 23;110(30):12325-30. doi: 10.1073/pnas.1300415110. Epub 2013 Jul 8.

12.

Paclitaxel and CYC3, an aurora kinase A inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cells.

Lin Y, Richards FM, Krippendorff BF, Bramhall JL, Harrington JA, Bapiro TE, Robertson A, Zheleva D, Jodrell DI.

Br J Cancer. 2012 Nov 6;107(10):1692-701. doi: 10.1038/bjc.2012.450. Epub 2012 Oct 4.

13.

nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer.

Frese KK, Neesse A, Cook N, Bapiro TE, Lolkema MP, Jodrell DI, Tuveson DA.

Cancer Discov. 2012 Mar;2(3):260-269. doi: 10.1158/2159-8290.CD-11-0242. Epub 2012 Feb 28.

14.

Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer.

Jacobetz MA, Chan DS, Neesse A, Bapiro TE, Cook N, Frese KK, Feig C, Nakagawa T, Caldwell ME, Zecchini HI, Lolkema MP, Jiang P, Kultti A, Thompson CB, Maneval DC, Jodrell DI, Frost GI, Shepard HM, Skepper JN, Tuveson DA.

Gut. 2013 Jan;62(1):112-20. doi: 10.1136/gutjnl-2012-302529. Epub 2012 Mar 30.

15.

Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma.

Cook N, Frese KK, Bapiro TE, Jacobetz MA, Gopinathan A, Miller JL, Rao SS, Demuth T, Howat WJ, Jodrell DI, Tuveson DA.

J Exp Med. 2012 Mar 12;209(3):437-44. doi: 10.1084/jem.20111923. Epub 2012 Feb 20.

16.

A novel method for quantification of gemcitabine and its metabolites 2',2'-difluorodeoxyuridine and gemcitabine triphosphate in tumour tissue by LC-MS/MS: comparison with (19)F NMR spectroscopy.

Bapiro TE, Richards FM, Goldgraben MA, Olive KP, Madhu B, Frese KK, Cook N, Jacobetz MA, Smith DM, Tuveson DA, Griffiths JR, Jodrell DI.

Cancer Chemother Pharmacol. 2011 Nov;68(5):1243-53. doi: 10.1007/s00280-011-1613-0. Epub 2011 Mar 23.

17.

Artemisinin and thiabendazole are potent inhibitors of cytochrome P450 1A2 (CYP1A2) activity in humans.

Bapiro TE, Sayi J, Hasler JA, Jande M, Rimoy G, Masselle A, Masimirembwa CM.

Eur J Clin Pharmacol. 2005 Nov;61(10):755-61. Epub 2005 Oct 29.

PMID:
16261361
18.

Frequency of -163 C>A and 63 C>G single nucleotide polymorphism of cytochrome P450 1A2 in two African populations.

Dandara C, Basvi PT, Bapiro TE, Sayi J, Hasler JA.

Clin Chem Lab Med. 2004;42(8):939-41.

PMID:
15387446
19.

Cytochrome P450 1A1/2 induction by antiparasitic drugs: dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells.

Bapiro TE, Andersson TB, Otter C, Hasler JA, Masimirembwa CM.

Eur J Clin Pharmacol. 2002 Nov;58(8):537-42. Epub 2002 Oct 2.

PMID:
12451431
21.

Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s.

Bapiro TE, Egnell AC, Hasler JA, Masimirembwa CM.

Drug Metab Dispos. 2001 Jan;29(1):30-5.

PMID:
11124226

Supplemental Content

Loading ...
Support Center